Posts

Recursion Reports Q1 2026 Financial Results and Business Update

on

INmune Bio Inc. Announces 2025 Results and Provides Business Update

on

Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update

on

Compugen Reports Third Quarter 2025 Results: Earnings Beat, Clinical Progress, and Cash Runway Extended

on

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

on

Seres Therapeutics Cuts 25% of Workforce Following FDA Feedback on Microbiome Therapy Trial

on

PMV Pharma's p53 Drug Shows Effect in Ovarian Cancer, but Financial Challenges Loom

on

AC Immune Narrows Pipeline and Cuts 30% Workforce to Extend Cash Runway

on

Abivax aces pair of phase 3 ulcerative colitis trials as end of cash runway looms

on

Over One-Third of Biotechs Face Cash Crunch, EY 2025 Report Finds

on

Arcturus Prunes Early-Stage Pipeline to Focus on mRNA Therapies

on

Lava cuts jobs by 30% after key drug discontinued

on